AMPHASTAR PHARMACEUTICALS, INC.

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, inhalation products, complex medications including biologics and interchangeable biosimilars, as well as various innovative drug delivery systems. Headquartered in Dover, United States. Here are key aspects of the company:

• Products & Services — Develops and markets BAQSIMI® (the first and only dry nasal spray to treat very low blood sugar), Iron Sucrose Injection for iron deficiency anemia in patients with chronic kidney disease, and various proprietary products and technological platforms.
• Market Position — Recognized as the provider of the #1 prescribed glucagon in the US and a recipient of a Drug Shortage Assistance Award from the U.S. Food and Drug Administration for efforts in preventing and alleviating critical drug shortages.
• Customers & Industries Served — Serves patients requiring treatments for hypoglycemia (low blood sugar) and iron deficiency anemia associated with chronic kidney disease, as well as broader markets needing complex medications derived from living cells or organisms. Amphastar Pharmaceuticals is known for its specialized focus on difficult-to-manufacture biopharmaceuticals and innovative drug delivery systems like dry nasal sprays.